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Abstract: Glycosaminoglycans (GAGs) are a class of biomolecules expressed virtually on all
mammalian cells and usually covalently attached to proteins, forming proteoglycans. They are
present not only on the cell surface, but also in the intracellular milieu and extracellular matrix.
GAGs interact with multiple ligands, both soluble and insoluble, and modulate an important role
in various physiological and pathological processes including cancer, bacterial and viral infections,
inflammation, Alzheimer’s disease, and many more. Considering their involvement in multiple
diseases, their use in the development of drugs has been of significant interest in both academia and
industry. Many GAG-based drugs are being developed with encouraging results in animal models
and clinical trials, showcasing their potential for development as therapeutics. In this review, the role
GAGs play in both the development and inhibition of cancer and inflammation is presented. Further,
advancements in the development of GAGs and their mimetics as anti-cancer and anti-inflammatory
agents are discussed.
Keywords: glycosaminoglycans; mimetics; heparin; heparan sulfate; chondroitin sulfate; dermatan
sulfate; hyaluronan; keratan sulfate; anti-cancer; anti-inflammation
1. Introduction
Glycosaminoglycans (GAGs) are linear polysaccharides whose disaccharide building blocks consist
of an amino sugar (d-glucosamine that is N-acetylated, or N-sulfated, or N-acetyl-d-galactosamine) and
either uronic acid (d-glucuronic acid or L-iduronic acid) or galactose. GAGs are sometimes referred
to as mucopolysaccharides as they were originally characterized in mucus membranes and mucosal
exudates. GAGs are differentiated from one another based on the type of monomeric unit, linkages
between each monomeric unit, the position of sulfate groups, and the degree of sulfation. Based on
these features, GAGs can be broadly classified into four different classes (Figure 1): chondroitin
sulfate/dermatan sulfate (CS/DS), heparin/heparan sulfate (HS), hyaluronan (HA), and keratan sulfate
(KS) [1].
GAGs are highly charged owing to negatively-charged carboxylic acid units present on the
uronic acid residues and sulfate groups present on most of the units. HA is the only GAG that is
not sulfated and, hence, is the least negatively-charged GAG, while heparin is the most negatively
charged. Although each of these GAGs has a predominant disaccharide component as mentioned
above, as a result of the non-template-driven biosynthetic pathway by which they are produced,
these disaccharides can be modified at multiple positions by sulfation, acetylation, and/or epimerization,
creating a tremendous amount of heterogeneity in any particular class of GAGs [2].
GAGs are involved in a myriad of biological functions. Most of the biological interactions
mediated by proteoglycans are believed to be primarily because of the GAG chains present on
Int. J. Mol. Sci. 2019, 20, 1963; doi:10.3390/ijms20081963 www.mdpi.com/journal/ijms
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their surface. Since GAGs make up the cell surface of almost all the cells in the body, they play
a major role in maintaining the structural integrity of cells and tissues. They bind to different protein
targets, primarily via electrostatic interactions between negatively-charged uronic acids and sulfate
groups and positively-charged amino acids in the protein. In addition to electrostatic interactions,
non-ionic interactions between GAGs and their binding partners are found to dictate the specificity
and selectivity of binding [3]. They are known to interact with cytokines, chemokines, growth factors,
and enzymes, leading to profound physiological effects on processes such as coagulation, growth,
infection, inflammation, tumor progression, metastasis, etc. (Table 1).
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Table 1. Different classes of GAG-binding proteins and their biological activities.
Class of Binding Proteins Physiological Function Example
Enzymes Coagulation Factor Xa [4]
Enzyme inhibitors Coagulation, inflammation Antithrombin III [4]
Cell adhesion proteins Cell adhesion,inflammation, metastasis
Platelet/endothelial cell adhesion
molecule-1 [5]
Extracellular matrix (ECM)
proteins Cell adhesion, matrix organization Annexin V [6]
Growth factors Mitogenesis, cell migration Fibroblast growth factor [7,8]
Chemokines Chemotaxis,signaling inflam ation IL-8 [9]
Morphogens Cell specification, tissuedifferentiation, development BMP-2 [10]
Lipid-binding proteins Lipid metabolism,cell membrane functions Lipoprotein lipase [11]
Pathogen surface proteins Pathogen infections Circumsporozoite [12]
Viral proteins Viral infections Glycoprotein D [13]
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Since GAGs are involved in a plethora of biological activities, their use in the development of
drugs has been of long interest in the pharmaceutical industry. Heparin, the first GAG-based drug,
is used as an anticoagulant for the treatment of thrombosis, thrombophlebitis, and embolism [14].
The therapeutic potential of GAGs and their mimetics for the treatment of many other diseased states,
including cancer, inflammation, infection, wound healing, lung diseases, Alzheimer’s disease, etc.,
are being actively studied [15]. In this review, however, only the role and therapeutic application of
GAGs and GAG mimetics in cancer and inflammation will be discussed.
2. Role of GAGs in Cancer
Interaction of GAGs with growth factors, growth factor receptors, and cytokines are implicated in
cancer growth, progression, and metastasis [16]. GAGs are found to be involved in multiple signaling
cascades required for angiogenesis, cancer invasion, and metastasis. Interestingly, some GAGs have
also been shown to play a role in the inhibition of tumor progression. Understanding the type of
interaction and the role these GAGs play in multiple cancer types has led to the development of various
therapeutic approaches and novel drugs to treat cancer [17].
2.1. Heparin/HS in Cancer
Heparan sulfate proteoglycans (HSPGs) through their core proteins and GAG side chains modulate
multiple functions of tumor cells and are involved in tumor growth, invasion, and metastasis [18,19].
HS has been shown to promote cell-cell and cell-ECM adhesion, inhibiting invasion and metastasis,
and a decrease in the levels of HS, as seen in some cancers, resulted in the malignant cells being more
invasive [7,20]. While the levels of HS are decreased in some cancers, others display modifications in their
sulfation pattern, which are shown to be responsible for cancer progression. For example, highly-sulfated
HS is shown to trigger cell proliferation through fibroblast growth factor 2 (FGF2) signaling, in melanoma
cells [8]. Additionally, in the case of colon cancer, these modifications were also found to be highly
dependent on the anatomical location (right-side vs. left-side) and the metastatic/non-metastatic nature
of the tumor. Surprisingly, metastatic right-sided colorectal cancers were found to exhibit fewer
changes to the structure of HS when compared to the non-metastatic tumors [21,22]. HS also plays
a crucial role in epithelial to mesenchymal transition (EMT) due to its ability to bind to growth factors
present in the tumor microenvironment [23].
HSPGs, such as syndecan-1 and syndecan-4, have been associated with breast cancer progression
by the formation of complexes with FGF2 and fibroblast growth factor receptor 1 (FGFR-1) [24]. It was
also shown that syndecan-4 expression promotes tumor adhesion and migration in melanoma cells [25].
Another class of HSPGs, glypican-3, is found to play a variable role in tumors. For example, it is shown
to promote tumor growth in hepatocellular carcinoma and melanoma by stimulating Wnt signaling [26],
whereas it inhibited tumor growth by inducing apoptosis in breast and ovarian cancers [18]. However,
glycosylphosphatidylinositol-anchored glypicans, when overexpressed, are associated with tumor
growth in hepatocellular carcinoma and melanoma.
Over-expression of heparanase (HPSE), an enzyme that cleaves HS chains of HSPGs at β-1,4
positions, has been shown to be involved in mechanisms promoting tumor growth, angiogenesis,
and metastasis [27–29]. HPSE also enhances the phosphorylation of Src and epidermal growth factor
receptor (EGFR), activating STAT3, which is associated with head and neck cancer progression [30].
It further stimulates an increase in the expression of both hepatocyte growth factor and syndecan-1,
resulting in an aggressive phenotype [31]. On the contrary, heparanse-2 inhibits the activity of HPSE,
thereby acting as a tumor suppressor [32].
Downregulation of human sulfatase-1 (SULF1), a heparin-degrading endosulfatase, observed in
breast cancer cells, is shown to increase cell migration and invasion [33]. Human sulfatase-2 (SULF2),
an HS 6-O-endosulfatase, was found to inhibit in vivo tumor growth in human breast cancer xenograft
models [34]. Conversely, in the case of lung cancer, it is shown to promote carcinogenesis [35].
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2.2. CS/DS in Cancer
CS/DS is involved in the regulation of critical cellular processes, such as proliferation, apoptosis,
migration, adhesion, and invasion [36]. The CS/DS side chains of chondroitin sulfate proteoglycans
(CSPGs) participate in various interactions within the ECM, which is of particular importance in
malignancy. For example, increased levels of versican, a CSPG, has been correlated with disease
progression in early-stage breast and prostate cancers [37,38]. Changes to the CS chains of versican
with enhanced expression of 6-O-sulfated and non-sulfated disaccharide units was observed in
a malignant phenotype of pancreatic cancer [39]. In the case of melanoma, increased levels of
melanoma-associated chondroitin sulfate proteoglycan (MCSP) are observed, which enhances integrin
function, thereby activating Erk1/2 and stimulating cell growth and motility [40].
Structural alterations to CS chains, especially their sulfation pattern, is associated with cancer
progression [41]. For example, chondroitin-4,6-disulfate or CS-E (Figure 2), a type of CS, is overexpressed
in multiple cancer types. High expression of CS-E is correlated with increased binding to vascular
endothelial growth factor (VEGF) in ovarian adenocarcinomas [42]. A higher proportion of CS-E was
found in the highly-metastatic LM660H11 lung carcinoma cell line, when compared to the P29 cell line
with low metastatic potential, suggesting the role of CS-E in metastasis [43]. It was also shown that
overexpression of CS-E causes colonization of osteosarcoma cells in the liver [44].
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Changes in the expression levels of CS biosynthetic enzymes are also found in certain cancers [21,22].
Chondroitin sulfate N-acetylgalactosaminyltransferase 2 (CSGALNACT2), which plays a critical role
in chain elongation during CS synthesis, is found to be downregulated in non-metastatic colorectal
cancers, both right and left [21]. Similar to HSPGs, these changes are also dependent on whether or not
a tumor is metastatic [21].
CS/DS are also shown to interact with the proteins involved in tumor growth and enhance their
activity [45]. For example, CS-A, in human fibrosarcoma cells, enhances the mitogenic activity of
platelet-derived growth factor-BB (PDGF-BB), which is involved in the growth of malignant cells
and angiogenesis. The presence of CS-A increases the efficiency of signaling between PDGF-BB and
tyrosine kinases. It was also observed that exogenous addition of CS-A enhances fibrosarcoma cell
adhesion, chemotaxis, and migration [46].
2.3. HA in Cancer
Increased levels of HA are found in multiple types of human cancers, including breast [47], lung [48],
and ovarian cancer [49]. Growth factors and chemokines present in the tumor microenvironment
are known to induce HA production [50]. On the other hand, low levels of HA are associated with
metastatic potential in squamous cell carcinoma [51] and melanoma [52].
CD-44, in the presence of high levels of HA, is found to interact with signaling receptors such as
EGFR to stimulate downstream pathways involving PI3k/Akt and/or mitogen-activated protein (MAP)
kinases promoting chemoresistance and breast cancer progression [53–55]. Moreover, degradation
of HA to smaller oligosaccharides by hyaluronidases is reported to induce cleaving of CD-44 in the
tumor microenvironment, leading to tumor progression, as seen in breast, ovarian, glioma, and colon
cancers [56,57].
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2.4. GAGs as Anti-Cancer Agents
Several researchers have worked on utilizing the involvement of GAGs in cancer to develop
therapeutics. For example, heparin, in addition to its anticoagulant properties, also possesses anti-cancer
properties [58,59]. However, its anticoagulant property limits its development as an anticancer agent.
Taking this into consideration, non-anticoagulant heparin analogs inhibiting heparanase in vitro and
in vivo have been developed [60–62].
A non-anticoagulant HS, isolated from the bivalve mollusk Nodipecten nodosus, has been
shown to inhibit P-selectin-mediated events such as metastasis of Lewis lung carcinoma cells [63].
Another modified non-anticoagulant heparin, SST0001 or Roneparstat, was developed by Sigma-Tau
Pharmaceuticals as a potent heparanase inhibitor [61]. SST0001 is 100% N-acetylated and 25% glycol
split high-molecular weight heparin, and hence, the microheterogeneity of the original heparin is
retained in it. In preclinical murine models, it showed a significant reduction in tumor volume in
multiple myeloma mice xenograft models and was also recently tested in Phase I clinical trials for
advanced multiple myeloma [61].
M402 or necuparanib is another molecule developed as a non-anticoagulant heparin [60].
It is obtained from depolymerization of low molecular weight heparin followed by oxidation and
borohydride reduction, resulting in a glycol split. It was found to inhibit multiple targets involved
in tumor progression and metastasis, including heparanase, VEGF, FGF2, P-selectin, and stromal
cell-derived factor-1α (SDF-1α). It showed a reduction in tumor metastasis and statistically-significant
survival benefits in preclinical studies [64]. However, the Phase II clinical study in combination with
nab-paclitaxel and gemcitabine for pancreatic cancer was terminated due to an insufficient level of
efficacy in the study population.
Desai and co-workers found that a particular non-anticoagulant hexasaccharide sequence of HS,
called HS06, selectively inhibited cancer-stem-cell (CSC) self-renewal and induced apoptosis in several
colorectal, breast, and pancreatic cell lines [65]. The inhibition of self-renewal was found to be because
of activation of p38α/β mitogen-activated protein kinase (MAPK), which led to inhibition of TCF4
signaling, a critical regulator of CSC self-renewal. Additionally, it was also found that either shorter or
longer saccharide sequences of HS were not able to inhibit CSCs as potently as HS06, portraying the
specificity of GAG–protein interactions.
Sasisekharan and coworkers utilized the differential substrate specificity of heparinase I (Hep I)
and heparinase III (Hep III) to generate different oligosaccharide GAG fragments from the tumor cell
surface [66]. Interestingly, the fragments generated from Hep I promoted tumor growth, whereas Hep
III generated fragments were found to inhibit tumor growth and metastasis. Further analysis showed
that these GAG fragments inhibited tumor growth in vivo in a dose-dependent fashion with >70%
reduction in primary tumor growth at a dose of 10 µg/kg/day in mice models.
Apart from heparin/HS GAGs, CS/DS-based targeting in cancer has also been widely studied.
Fucosylated CS (FucCS), isolated from sea cucumber, was found to inhibit tumor metastasis in vivo by
blocking P- and L-selectin-mediated events [67]. Exogenous CS-A has been shown to be effective in
decreasing monocyte migration, thereby preventing angiogenesis in vitro [68]. Novel molecules called
neoglycans, produced by modifying CS chains with carbodiimide, reduced tumor growth in nude
mice with breast cancer without apparent toxicity to the normal tissue [69]. These studies prove the
potential use of GAGs or modified GAGs as potent anticancer agents.
3. Role of GAGs in Inflammation
Inflammation is a defense mechanism of the body to harmful stimuli. This protective action
primarily involves the recruitment of immune cells from the bloodstream into the site of injury/infection.
Some of the major events during the inflammation process are intimately regulated by GAGs, especially
those coating the surface of endothelial cells and leukocytes [70–75]. At the site of injury/infection,
GAGs are involved in leukocyte rolling along the endothelial surface; regulation of chemokine
migration and activation; and trans-endothelial migration of leukocytes.
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Upon inflammatory trigger, macrophages at the site of infection/injury release cytokines,
which activate endothelial cells, resulting in the display of P-selectins on their surface. P-selectin
glycoprotein ligand-1 (PSGL-1) on leukocytes interact with activated endothelial cells by binding
to P-selectins. The PSGL-1-P-selectin interaction enables leukocytes’ adhesion onto the endothelial
layer [70]. Upon leukocyte adhesion on the endothelial cells, HS on the surface of endothelial cells
binds to L-selectins on leukocyte, leading to leukocyte rolling [71]. Regulation of leukocyte rolling is
the first role of GAGs in inflammation.
Macrophages at the site of infection/injury also release significant amounts of chemokines, in
addition to cytokines. The released chemokines, particularly IL-8 (CXCL-8), bind to GAGs at the
endothelial surface, leading to chemokine transcytosis [72]. After transcytosis across the endothelial
layer, leukocytes are recruited by the interaction of integrin on leukocytes with intercellular adhesion
molecule-1 (ICAM-1) on the endothelial surface. This interaction leads to increased adhesion of
leukocytes onto the endothelium, thereby slowing down the rolling of leukocytes. This triggers
morphological changes required for the migration of leukocytes through the endothelial barrier.
Syndecan, a proteoglycan containing HS chains, plays a major role in this migration process [73].
Heparin is synthesized and stored in certain types of mast cells and is co-released with histamine
upon inflammatory trigger [74]. Released heparin induces the formation of bradykinin and helps in
vascular permeability [75].
GAGs as Anti-Inflammatory Agents
Due to the tremendous role played by GAGs throughout the inflammation process, exogenous
sulfated glycans of various structures can be used to downregulate inflammation processes. Many such
molecules have been tested in in vitro and in vivo models, and some have even reached clinical trials.
Besides its use as an anticoagulant, heparin demonstrated excellent anti-inflammatory properties
in animal models and clinical trials [76]. Heparin has been shown to be useful for the treatment of
bronchial asthma [77], ulcerative colitis [78], and burns [79]. Although these studies showed promising
results, heparin is not approved for use as an anti-inflammatory agent because of the associated
bleeding risk. Several non-anticoagulant heparin mimetics were developed thereafter to maintain its
anti-inflammatory effect [80]. One such example is 2-O,3-O-desulfated heparin (ODSH), which was
shown to reduce airway inflammation by potently inhibiting human neutrophil elastase without
any anticoagulant effects [81]. Another non-anticoagulant heparin isolated from shrimp Litopenaeus
vannamei has significantly reduced the influx of inflammatory cells to the site of injury in acute
inflammation models [82].
Exogenous DS of a specific length is found to inhibit P-selectins in inflammatory mouse models [83].
On the other hand, CS is found to inhibit inflammation in rat astrocytes by preventing NF-κB
activation [84].
KS has been shown to ameliorate the pathological conditions associated with inflammation [85].
For example, exogenously-added KS reduced damage in cartilage explants that were exposed to
interleukin-1α ex vivo. Since cartilage fragments can cause an antigenic response, resulting in an increase
in inflammation and arthritic response, reduced cartilage degradation can be correlated to a reduction
in the severity of arthritis [86]. In addition, when tested in vivo using a murine arthritis model, KS was
found to ameliorate arthritis [86]. Plasma levels of KS have been identified as a potential biomarker
for joint damage in juvenile idiopathic arthritis [87]. In the cornea, KS proteoglycans are found to
bind to chemokine CXCL1 and facilitate its migration into the stroma during inflammation [88].
The addition of low molecular weight KS resulted in the disruption of this KS-CXCL1 complex, leading
to efflux of chemokines and resolution of inflammation [89]. In a study by Taniguchi and coworkers,
a KS disaccharide, [SO3−-6]Galβ1-4[SO3−-6]GlcNAc, prevented neutrophil-mediated inflammation
and progression of emphysema in murine models, indicating its potential use for the treatment of
inflammation in chronic obstructive pulmonary disease [90,91].
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These works clearly indicate the potential of using GAGs and related compounds as
anti-inflammatory agents.
4. GAG Mimetics
Although GAGs have tremendous applications as therapeutics, there are many challenges
associated with their structure, halting their success in clinical trials. As previously mentioned,
GAGs are complex heterogeneous molecules with exceptional structural diversity, which not only
differ in their length, but are also modified at multiple positions through sulfation, acetylation,
and epimerization. This inherent heterogeneity involved in the biosynthesis of GAGs leads to
a particular GAG binding to many different proteins, thus compromising selectivity and leading to
side-effects when given as a therapeutic [16,92].
Furthermore, GAGs are usually obtained from animal sources. For example, heparin, one of the
oldest drugs in the clinic, is obtained from porcine intestine, bovine intestine, and bovine lung. Hence,
the quality of heparin obtained depends on the environmental conditions and the diet each animal is
exposed to and results in significant batch-to-batch variation [93]. The heterogeneity of GAGs makes
the complete characterization of every batch of heparin produced nearly impossible, thereby making
quality control a daunting task [94]. In 2008, contamination of heparin with over-sulfated CS resulted
in over 200 deaths and thousands of adverse effects in the United States alone [95].
To address the issues involved in the development of GAGs as therapeutics, multiple strategies
have been developed to mimic GAGs through small molecules called GAG mimetics [92]. GAG mimetics
have numerous advantages over GAGs as therapeutics. They are usually completely synthetic and
homogenous molecules and hence are expected to have increased selectivity and fewer adverse
effects [96]. They are easier to produce at large scales, design computationally, characterize, and quality
control. They also have better pharmacokinetic features than GAGs, making them more ‘drug-like’.
GAG mimetics can be classified into two classes: saccharide-based and non-saccharide-based.
Saccharide-based GAG mimetics, although built on a sugar backbone, are synthetic and not produced
from animal sources. They are less heterogeneous when compared to GAGs. On the other hand,
non-saccharide-based mimetics utilize non-sugar-based scaffolds carrying negative charges through
sulfates, sulfonates, carboxylates, and/or phosphates. They are completely homogenous molecules and
provide numerous advantages over saccharide-based mimetics. Both saccharide and non-saccharide
GAG mimetics have been developed for the treatment of cancer and inflammation, and a few are
currently in clinical trials, while some are marketed in the clinic. Here, I discuss the GAG mimetics that
have shown remarkable potential and made huge advancements in the fields of cancer and inflammation.
4.1. GAG Mimetics as Anti-Cancer Agents
4.1.1. Saccharide-Based GAG Mimetics
Phosphomannopentaose sulfate (PI-88; Figure 3A) is an HS mimetic obtained via sulfation of
the phospho-mannan complex produced from yeast cultures [97]. It is a heterogeneous mixture of
di- to hexa-saccharides, but mostly tetra- (60%) and penta-saccharides (30%). PI-88 potently inhibits
the activity of heparanase, an enzyme that plays a vital role in metastasis and angiogenesis. It was
also found to bind to pro-angiogenic growth factors VEGF, FGF1, and FGF2 by competing with HS.
Although PI-88 also possesses anticoagulant activity, in addition to anticancer activity, it appeared to
be well tolerated in preclinical models and was hence investigated further in clinical trials. It reached
Phase III clinical trials for hepatocellular carcinoma, which was concluded after interim analysis due to
the failure to reach the primary disease-free survival endpoint [98].
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Several second-generation analogs of PI-88 that are anomerically pure, completely sulfated,
and homogeneous were later developed by Progen Pharmaceuticals Ltd. Among these analogs, PG545
or pixatimod (Figure 3B) was selected as the lead compound [99]. In addition to being a fully-sulfated,
anomerically-pure, homogenous compound, PG545 has a lipid moiety attached at the reducing end,
which resulted in improved pharmacokinetic properties and reduced anticoagulant activity [100].
It also resulted in increased affinity towards heparanase as a result of the lipid moiety’s binding in
the hydrophobic pocket [101]. It showed potent antitumor and anti-metastatic activity in several
preclinical models and is currently in Phase I clinical trials for advanced solid tumors and metastatic
pancreatic cancer.
Dollé and coworkers synthesized an octasaccharide heparin mimetic that interfered with the
process of angiogenesis and metastasis [102]. It potently inhibited heparanase, FGF2, VEGF, SDF-1α,
PDGF-β, and cell proliferation in vitro and is being tested in vivo in animal models.
4.1.2. Non-Saccharide GAG Mimetics
A library of small HS mimetics was developed by Parish and co-workers from sulfation
of cyclitols [103]. They screened the library of 15 molecules against a panel of GAG binding
proteins and observed a clear relationship between the structure and the protein they recognized.
They found that Compound a (Figure 4A) with an ethyl linker was a potent inhibitor of FGF-1,
and Compound b (Figure 4A) with an octyl linker was a potent inhibitor of FGF-2 and VEGF, but not
FGF-1. These compounds, because of their ability to inhibit different growth factors, are expected to
possess antitumor activity.
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Desai and co-workers reported the development of HS mimetics that inhibit angiogenesis [104].
By screening a library of 18 sulfated-small molecules belonging to different chemical classes (flavone,
flavan, chalcone, stilbene, styrene, and isoquinoline scaffolds), they identified potent molecules
(Figure 4B) that inhibited the formation of angiogenesis at a 100 µM concentration.
They also reported the development of a small molecule GAG mimetic selectively targeting
colon CSCs [105]. They developed a tandem, dual-screen strategy to screen selectively for molecules
targeting CSCs over the population of bulk c ncer cells. Using thi screening protoc l nd olecular
dynamics-based algorithm, they showed that G2.2 (Figure 4C) is a structural a d unctional mimetic
of HS06. G2.2 inhibited the growth of CSCs from multiple cell lines by induction of apoptosis and
inhibition of self-renewal factors. G2.2 also inhibited the growth of tumor in CSC induced xenografts
in vivo [106].
Another recent study highlighted the use of polyproline-based GAG mimetics (PGMs) that
recapitulate key structural features of GAGs, including periodicity, the length of repeating units,
turnability, and helicity, as shown through molecular dynamics simulations [107]. One of the synthesized
PGMs, {Z}12 (Figure 4D), inhibited the interaction of CS-E with P-selectin, which is implicated in
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metastasis and inflammation. It also reduced metastasis in vivo as effectively as heparin and tinzaparin.
Additionally, {Z}12 did not have inhibitory effects on the coagulation cascade enzymes, resulting in
no/minimal bleeding side-effects. In animal models, it did not induce weight loss, elevate liver damage
markers, or cause histopathological abnormalities, suggesting its safe use in vivo.
4.2. GAG Mimetics as Anti-Inflammatory Agents
4.2.1. Saccharide-Based GAG Mimetics
GlycoMimetics Inc. has developed a pan-selectin antagonist, GMI-1070 (Figure 5A), to treat
vascular occlusions in people with sickle cell disease [108]. Recurrent vascular occlusions, as seen in
sickle cell disease, lead to chronic inflammation and, eventually, irreversible organ damage. GMI-1070,
when administered in mice, resulted in an increase in leukocyte rolling, which is indicative of selectin
inhibition. It reduced leukocyte adherence to endothelium, inhibited red blood cell and leukocyte
interactions, and also inhibited vascular occlusion. It was demonstrated to be safe in Phase I clinical
trials [109], reduced the time to resolve vascular occlusive events in Phase II [110], and is currently in
Phase III clinical trials.
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disaccharide (SSD), and (D) KanCbz and NeoCbz.
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Fukada and co-workers identified a synthetic, non-natural monosaccharide, 2,4-O-di-sulfated
iduronic acid (Di-S-IdoA; Figure 5B), as an inhibitor of CCL20-HS interaction by screening a glycan
array [111]. It also inhibited the binding of CXCL8 and L-selectin. The in vivo effects of the compound
in mice models of allergy were tested via tail vein injection or nasal inhalation. Di-S-IdoA showed
a reduction in leukocyte recruitment into the lungs, indicating a potential use of the compound to
reduce the inflammatory response.
Another study showed the development of a super-sulfated disaccharide sequence of heparin
(Hep-SSD; Figure 5C) from a non-anticoagulant inactive disaccharide [112]. Hep-SSD inhibited allergic
airway responses in a sheep model of allergic asthma when given by both aerosol and oral administration
routes in a dose-dependent manner.
Kerns and co-workers screened a panel of N-arylacyl-O-sulfated aminoglucosides against
neutrophil serine proteases, including human neutrophil elastase, proteinase 3, and cathepsin G,
which are upregulated in inflammatory lung conditions such as chronic obstructive pulmonary
disease, cystic fibrosis, and acute lung injury [113]. They identified two lead compounds (Figure 5D),
a kanamycin-based compound (KanCbz) and a neomycin-based compound (NeoCbz), as potent
inhibitors of one or more of the proteases. The results demonstrated that these lead compounds can be
further exploited for multi-target inhibitor drugs for attenuating inflammation mediated by proteases.
RGTA®s (ReGeneraTing Agents; Figure 6) are another class of HS mimetics that are designed to
replace degraded HS in the ECM of injured tissue [114]. Chemically, they are polymers of dextran with
~250 glycan residues substituted with sulfates and carboxyl groups to mimic HS. In contrast to HS,
which is made of β1-4 glycosidic bonds, RGTA®s are linked by α1-6 carbon-carbon bonds. This makes
their structure resistant to enzymatic degradation (chondroitinase ABC, dextranase, hyaluronidase,
and heparinases I, II, and III), helping them retain their structure and activity even in the presence of
chronic wounds and inflammation. The ability of these compounds to improve wound healing has
been intensively studied in numerous pathological conditions, and they are currently in the clinic for
the treatment of chronic skin and corneal lesions.
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4.2.2. Non-Saccharide GAG Mimetics
The ability of sulfated low molecular weight lignins to inhibit inflammation caused by human
neutrophil elastase, for the treatment of emphysema, was studied by Desai and co-workers.
They found that sulfated caffeic acid (CDSO3; Figure 7) inhibited human neutrophil elastase in
a concentration-dependent manner with an IC50 of 0.43 ± 0.04 µM and showed anti-oxidative and
anti-inflammatory properties in vitro [115]. Furthermore, it attenuated the development of emphysema
in rat models where emphysema was induced with human neutrophil elastase and cigarette smoke
extract [116]. It was able to reduce inflammation in both a preventive and interventional manner when
administered locally to the lung with doses as low as 30–100 µg/kg.
When endothelial lung cell death was induced in vitro using inhibitors for histone deacetylase
and VEGF receptor, or through cigarette smoke, CDSO3 treatment significantly inhibited cell death
when compared to control [117]. In a rat model with induced apoptotic emphysema, 60 µg/kg of
CDSO3 produced significant blockade of lung damage and resulted in increased exercise endurance.
Overall, CDSO3 appears to be promising in developing a novel treatment for emphysema.
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RNA, and proteins, and sugars were considered as a mere source of energy, lacking any other 
biological activities. Hence, the majority of research was focused on understanding the roles DNA, 
RNA, and proteins play in different physiological and pathological conditions. Furthermore, studies 
on glycans lagged far behind other macromolecules because of limited technology available to study 
their structural diversity and complexity. With advancements in mass spectrometry, lectin and 
antibody arrays, imaging technologies, glycan microarrays, and bioinformatic tools, it has now 
become possible to study the glycome, expanding the field of glycobiology. 
Today, glycans are known to play diverse roles in an organism. GAGs, in particular, regulate a 
multitude of functions by interacting with proteins, cells, and tissues in the human body. They play 
a major role in almost every physiological activity in the body and are essential in maintaining 
homeostasis. Moreover, changes in their expression and/or the structure of GAGs are observed in 
multiple pathological conditions and are being employed as biomarkers for disease progression. 
Since the discovery of heparin, more than 100 years ago, GAGs have been widely studied as 
therapeutics for cancer, inflammation, infections, lung diseases, etc. However, their success is being 
halted because of their inherent heterogeneity and affinity towards multiple targets, leading to  
side-effects. As a result of dealing with the limitations of GAGs, there seems to be a drift from 
heterogeneous GAGs derived from animal sources to homogenous, synthetic, or semi-synthetic GAG 
mimetics. These GAG mimetics not only offer advantages with homogeneity and synthetic feasibility, 
but also (usually) possess increased potency, selectivity, and better pharmacokinetic properties with 
lesser adverse effects. In conclusion, the field of glycosaminoglycan drug discovery is rapidly 
progressing with multiple GAGs/GAG mimetics already in the clinic. The next decade is going to see 
major changes in both the structural studies of GAGs and their corresponding role in therapy with 
more GAG-based drugs making their way to the clinic and rewriting the historical notion of GAGs 
in drug discovery. 
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5. Conclusions
In the past, he biological information of an organism was con dered to be stored in the DNA,
RNA, and prot ins, and sugars were considered as a mere so rce of energy, lacking any other biological
activities. Hence, the m jority of research was focused on ndersta ding the roles DNA, RNA,
and proteins play in different phys olo ical and pathological conditio s. Furthermore, studies on
glycans lagged far behind other macromolecules because of limited technology available to study their
structural diversity and complexity. With advancements in mass spectrometry, lectin and antibody
arrays, imaging technologies, glycan microarrays, and bioinformatic tools, it has now become possible
to study the glycome, expanding the field of glycobiology.
Today, glycans are known to play diverse roles in an organism. GAGs, in particular, regulate
a multitude of functions by interacting with proteins, cells, and tissues in the human body. They play
a major role in almost every physiological activity in the body and are essential in maintaining
homeostasis. Moreover, changes in their expression and/or the structure of GAGs are observed in
multiple pathological conditions and are being employed as biomarkers for disease progression.
Since the discovery of heparin, more than 100 years ago, GAGs have been widely studied
as therapeutics for cancer, inflammation, infections, lung diseases, etc. However, their success is
being halted because of their inherent heterogeneity and affinity towards multiple targets, leading
to side-effects. As a result of dealing with the limitations of GAGs, there seems to be a drift from
heterogeneous GAGs derived from animal sources to homogenous, synthetic, or semi-synthetic GAG
mimetics. These GAG mimetics not only offer advantages with homogeneity and synthetic feasibility,
but also (usually) possess increased potency, selectivity, and better pharmacokinetic properties with
lesser adverse effects. In conclusion, the field of glycosaminoglycan drug discovery is rapidly
progressing with multiple GAGs/GAG mimetics already in the clinic. The next decade is going to see
major changes in both the structural studies of GAGs and their corresponding role in therapy with
more GAG-based drugs making their way to the clinic and rewriting the historical notion of GAGs in
drug discovery.
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Abbreviations
GAG Glycosaminoglycan
HA Hyaluronan
CS Chondroitin sulfate
DS Dermatan sulfate
HS Heparan sulfate
KS Keratan sulfate
HSPG Heparan sulfate proteoglycan
FGF2 Fibroblast growth factor 2
EMT Epithelial to mesenchymal transition
FGFR-1 Fibroblast growth factor receptor-1
EGFR Epidermal growth factor receptor
CSPG Chondroitin sulfate proteoglycan
VEGF Vascular endothelial growth factor
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PDGF Platelet-derived growth factor
MAPK Mitogen-activated protein kinase
CSC Cancer-stem cell
ODSH 2-O, 3-O-desulfated heparin
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